A Randomised, Double-blind (for GW870086), Placebo-controlled Study of Topical GW870086 Formulation to Explore the Potential for Skin Thinning in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2017
At a glance
- Drugs GSK 870086 (Primary) ; Clobetasol
- Indications Asthma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 28 Jul 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 28 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jun 2011 New trial record